Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical services provider Ergomed appointed Richard Barfield FCA as Chief Financial Officer, effective immediately.
Barfield replaced Stuart Jackson, who was set to leave Ergomed to return to the energy sector, as announced earlier this year in February.
Since qualifying as a chartered accountant, Barfield has had more than 25 years' experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience.
Barflied has had proven experience within the contract research sector having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO, the company said.